Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 5/20 | 0.58 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 2/20 | 0.55 |
| ▸ | LOX | P28300 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL919885 | 0.98 | LOXL2 (0.57) | LOXL2ST14MAOBLOXKDM4E | |
| Hydrazine SCHEMBL15923213 | 0.96 | LOXL2 (0.54) | LOXL2ST14MAOBLOXKDM4E | |
| SCHEMBL4949955 | 0.94 | ST14 (0.58) | LOXL2ST14MAOBLOXALDH1A1 | |
| SCHEMBL29215392 | 0.89 | ALDH1A1 (0.57) | LOXL2ST14MAOBLOXKDM4E | |
| SCHEMBL27907657 | 0.89 | LOXL2 (0.47) | LOXL2ST14MAOBLOXKDM4E | |
| SCHEMBL12167626 | 0.86 | ALDH1A1 (0.68) | LOXL2ST14MAOBALDH1A1TDP1 | |
| SCHEMBL100121 | 0.85 | LOXL2 (0.52) | LOXL2ST14MAOBLOXALDH1A1 | |
| SCHEMBL184274 | 0.85 | ST14 (0.55) | LOXL2ST14MAOBLOXALDH1A1 | |
| SCHEMBL920590 | 0.85 | ST14 (0.55) | LOXL2ST14MAOBKDM4EALDH1A1 | |
| SCHEMBL921786 | 0.85 | ALDH1A1 (0.55) | ST14MAOBALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140316107-A1 | CYCLIN BASED INHIBITORS OF CDK2 AND CDK4 | UNIVERSITY OF SOUTH CAROLINA | 2014-10-23 | — | — | US | claimed |
| US-20110257365-A1 | Cyclin Based Inhibitors of CDK2 and CDK4 | UNIVERSITY OF SOUTH CAROLINA (US) | 2011-10-20 | — | — | US | claimed |
| CN-100410236-C | Substituted methylene amide derivatives as protein tyrosine phosphatase modulators | APPLIED RESEARCH SYSTEMS (CH) | 2008-08-13 | — | — | CN | claimed |
| CN-1933827-A | Use of methylene amide derivatives in cardiovascular disorders | APPLIED RESEARCH SYSTEMS (AN) | 2007-03-21 | — | — | CN | claimed |
| CN-1633410-A | Substituted methylene amide derivatives as protein tyrosine phosphatase modulators | APPLIED RESEARCH SYSTEMS (AN) | 2005-06-29 | — | — | CN | claimed |
| JP-61152646-A | — | — | None | — | — | JP | disclosed |
| US-RE50878-E1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2026-05-05 | — | — | US | disclosed |
| US-20250034139-A1 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | PHARMA CINQ, LLC | 2025-01-30 | — | — | US | disclosed |
| US-12139483-B2 | Imidazoquinolyl compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity | PHARMA CINQ, LLC (US) | 2024-11-12 | — | — | US | disclosed |
| CN-118076767-A | Method and formulation for producing an optical metal oxide layer | 默克专利有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20240018153-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO, INC. (CA) | 2024-01-18 | — | — | US | disclosed |
| US-20240018153-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO, INC. (CA) | 2024-01-18 | — | — | US | disclosed |
| EP-0313397-A1 | Therapeutic heterocyclic compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1989-04-26 | — | — | EP | disclosed |
| JP-S61152646-A | AMIDE COMPOUND, PREPARATION THEREOF, AND CONTROLLING AGENT CONTAINING SAME | SUNTORY LTD | 1986-07-11 | — | — | JP | disclosed |
| EP-0006180-B1 | 3-PHENOXYBENZYLIDENE AMINES AND 3-BENZYLBENZYLIDENE AMINES, PROCESS FOR THEIR PREPARATION AND THEIR USE TO PREPARE THE CORRESPONDING ALDEHYDES | CIBA-GEIGY AG (CH) | 1981-02-11 | — | — | EP | disclosed |
| US-4231962-A | 3-Phenoxybenzylideneamines and 3-benzylbenzylideneamines | CIBA-GEIGY CORPORATION (US) | 1980-11-04 | — | — | US | disclosed |
| EP-0006155-A1 | 3-Phenoxybenzyl amines and 3-benzylbenzyl amines and process for their production | CIBA-GEIGY AG (CH) | 1980-01-09 | — | — | EP | disclosed |
| EP-0006155-A1 | 3-Phenoxybenzyl amines and 3-benzylbenzyl amines and process for their production | CIBA-GEIGY AG (CH) | 1980-01-09 | — | — | EP | disclosed |
| EP-0006155-A1 | 3-Phenoxybenzyl amines and 3-benzylbenzyl amines and process for their production | CIBA-GEIGY AG (CH) | 1980-01-09 | — | — | EP | disclosed |
| EP-0006180-A1 | 3-Phenoxybenzylidene amines and 3-benzylbenzylidene amines, process for their preparation and their use to prepare the corresponding aldehydes | CIBA-GEIGY AG (CH) | 1980-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140316107-A1 | CYCLIN BASED INHIBITORS OF CDK2 AND CDK4 | CDK4, CDK2, CDK2AP2 | LOXL2 4285/4885ST14 954/4885MAOB 4545/4885 |
| US-20110257365-A1 | Cyclin Based Inhibitors of CDK2 and CDK4 | CDK4, CDK2, CDK2AP2 | LOXL2 4285/4885ST14 954/4885MAOB 4545/4885 |
| US-20250034139-A1 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | AADAC, CASP1, AAAS | LOXL2 3154/4885ST14 3833/4885MAOB 248/4885 |
| US-12139483-B2 | Imidazoquinolyl compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity | NOD1, NLRP3, AADAC | LOXL2 3179/4885ST14 4029/4885MAOB 1777/4885 |
| US-20240018153-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | ABCG2, ABCB1, ARSA | LOXL2 2056/4885ST14 2526/4885MAOB 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.